Bio/Pharma Business

The new center will serve as a regional hub where scientists and engineers can work with customers for biological development.

The company is considering options for a full or partial separation of its Consumer Healthcare business, either through a spin-off, sale, or other transaction.

Reeling from financial and tropical storms, Puerto Rico needs stable industry for recovery.

Biopharmaceutical companies developing new competitive biotech therapies have pressed hard for clarity on the testing and data required by FDA to gain market approval of biosimilars that can be filled by a pharmacist without prescriber preapproval.

Faced with divisive political and social issues, Congress must find a way to reach consensus.

David McKelvey, director of TM Eye, a detective company based in the United Kingdom, provides insight into the counterfeit pharmaceuticals business.

On August 3, 2017, Bristol-Myers Squibb (BMS) announced that it has agreed to acquire biotech firm, IFM Therapeutics, in a deal worth over $1 billion to develop BMS’ oncology pipeline.

Charles River Labs has announced the acquisition of Brains On-Line (US), a contract research organization (CRO) that provides data on therapeutics for treating central nervous system (CNS) diseases.

EMA recognizes the need to provide more assistance and guidance to SMEs developing new medicines and applying for marketing authorizations.

JLL ranks top 10 US life-sciences locations where scientists prefer to work and finds that location and workplace culture are key priorities.

A June conference at Johns Hopkins examined the potential for digital ledgers and smart contracts in pharma and healthcare

Drug costs, biosimilars, and cloud-based technologies will shape the pharmaceutical industry in the years to come.

Pharma company consolidation and outsourcing led to a de-emphasis of manufacturing and reduced investment in new technologies and facilities.

Cheaper drugs are good for consumers, but cost restrictions limit drug company incentives to modernize facilities.

Regulations and business changes have altered Big Pharma’s place in the industry.

Pharmaceutical Technology marks 40 years of publishing.

In Lazard's Global Healthcare Leaders 2017 survey, most respondents said pricing and reimbursement were the most significant challenge, but nearly half of the pharma executives who responded see value-based pricing as having the greatest impact on the business, potentially even more than scientific breakthroughs.

A rigorous approach to industrial security is essential for protecting intellectual property and product integrity in connected pharmaceutical operations.

New study will reveal bio/pharma practices and performance on quality issues.

New study shows China biopharma companies face staffing shortages.

A blog posted on Health Affairs on March 7, 2017 presents a study that tested PhRMA’s long-standing argument that high prices for drugs fund research and development in the pharmaceutical industry.

Drug type, potential sales, and ownership factor in the race to get drugs to market.

The authors discuss regulatory and patent issues with combination products.

The trends in the year 2017 will present the industry with new challenges, and companies will be able to meet them successfully if they focus on the issues at hand.

Drug companies are pushing Congress to action on funding for FDA programs and staff to expedite drug reviews and approvals.

Pharmaceutical Technology spoke with Tommy Fanning, head of biopharmaceuticals for IDA Ireland, to get a perspective on how Brexit may affect the pharmaceutical industry.

Top C-suite leaders are already tuning their long-range planning, hiring practices, and business systems for elasticity. Are you ready?

Translating campaign promises to predictions for bio/pharma is difficult, but optimism prevails.

Healthcare policies, R&D investments, and drug approvals will test bio/pharma.

Estimates that global medicine spending will reach nearly $1.5 trillion by 2021 and the types of therapies and use of innovator versus generic drugs, will vary by region.